Groowe Groowe / Newsroom / RDHL
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

RDHL News

Redhill Biopharma Ltd.

RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation

prnewswire.com
RDHL CPIX

RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo

prnewswire.com
RDHL CPIX

RedHill Biopharma Advancing Opaganib Options For Ebola Virus Disease Outbreak

prnewswire.com
RDHL

RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms

prnewswire.com
RDHL

Hepatic Encephalopathy Market Set for Growth at a 1.2% CAGR Through 2036, Driven by Emerging Therapies and Rising Disease Burden | DelveInsight

globenewswire.com
VNDA GRFS BHC RDHL MRK TEVA PFE SNY LLY ABBV AZN CRCT SPRO CRNX

RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease

prnewswire.com
RDHL CPIX

RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights

prnewswire.com
RDHL CPIX

RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026

prnewswire.com
RDHL CPIX

H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsight

prnewswire.com
RDHL CPIX PHAT

Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight

prnewswire.com
CMPX MRK PFE BOLD REPL RDHL RLAY LLY INCY JAZZ